Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2012

View Archived Issues

Fifth phase III study of QVA-149 meets primary endpoint

New Afinitor formulation approved in U.S.

Creabilis products show promise as topical analgesics

PAR1 receptor antagonist prevents heart failure-induced atrial remodeling

Topical cream improves female sexual arousal disorder in phase III trial

Research at Kyowa Hakko Kirin produces new calcium channel antagonists

Merck KGaA patents novel protein kinase inhibitors

Novel inhibitors of JAK3 presented

New heat shock protein inhibitors designed in Japan

Lead product for Parkinson's disease advances through preclinical studies

Zinc peptidase implicated in ACS pathogenesis

Humira indication broadened in Europe

Enrollment complete in phase Ib trial of CALAA-01

ARIAD submits MAA to EMA

PharmaMar product gets orphan drug designation

Exelixis provides update on FDA meeting for cabozantinib

Infradure tissue implant cleared for two hepatitis C trials in Israel

Genmab and Janssen Biotech form worldwide agreement

New drug approved for IBS-C and CIC

Sunovion signs definitive acquisition agreement

FDA grants orphan drug designation to ARLN-05

Lead Nordic Nanovector product clear to enter clinic

Bayer HealthCare submits NDA for regorafenib

New genetic test predicts response to antipsychotics/antidepressants

PR-610 enters phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...